MUNICH – Definiens, the global leader in image analysis for digital pathology and diagnostics announced today the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer. Definiens’ proprietary Cognition Network Technology® is core to automatically classify and quantitate key tissue features as part of Clarient’s Scope IA Platform offering to its pathology customers. 

“At Clarient, we combine world class pathology with innovation and our goal is to make a difference to physicians and their patients,” said Kenneth Bloom, MD, Chief Medical Officer, Clarient Diagnostic Services, Inc. “Our work with Definiens will enable us to offer high quality, robust readouts with fast turnaround time. This means physicians will have better patient insights for diagnosis.” 

“We are really pleased to work with Clarient on creating these validated applications for their routine clinical work. Running thousands of patient slides through our algorithms and seeing the computer-aided diagnosis in action is really gratifying,” said Thomas Heydler, CEO of Definiens. “No one else has done this on such a large scale.” 

Definiens’ Cognition Network Technology® was invented by 1986 Nobel prize winner Gerd Binnig and is unique in its ability to extract information from tissue images, a process known as tissue datafication™. Definiens applies the technology for solutions in discovery, preclinical, and diagnostic imaging. 

About Definiens

Definiens is the leading provider of image analysis solutions and data mining solutions for life science, tissue diagnostics, and clinical digital pathology. Definiens’ technology provides detailed biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information, an approach known as Tissue Phenomics™. Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. 
Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine, and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany and has its North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.